EGFR and cancer: These mutations increase the kinase activity of EGFR and eliminate the dependence of the cancer mutants on EGF binding for activation, leading to stimulation of downstream pro-survival and cell-growth pathways, and consequently conferring oncogenic properties on EGFR.